Posted by Michael Wonder on 31 May 2017
New action plan to support SMEs as drivers of pharmaceutical innovation
31 May 2017 - 16 actions identified for implementation in 2017-2020.
The EMA has published today an action plan for small and medium-sized enterprises (SMEs), which aims to foster innovation and support SMEs in the development of novel human and veterinary medicines.
SMEs are the backbone of Europe's economy. They represent 99% of all businesses in the European Union and provide two-thirds of total private sector employment. In the pharmaceutical sector SMEs are a motor of innovation and play a major role in the development of new medicines.
To support SMEs throughout all stages of medicine development, EMA’s SME Office provides active regulatory, financial and administrative support to registered SMEs. More than 1,700 companies are currently registered with the Agency operating in the human and veterinary fields.
